Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Hookipa Pharma Inc (NASDAQ:HOOK) Chief Executive Officer Malte Peters sold 25,172 shares of common stock on August 19, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $0.8217, for a total transaction value of $20,683. The sale comes as the stock trades near $0.93, down roughly 76% over the past year, according to InvestingPro data.
The prices for the sales ranged from $0.8205 to $0.8225. Following the transaction, Peters directly owns 54,347 shares of Hookipa Pharma Inc , which currently has a market capitalization of $11.37 million. InvestingPro analysis indicates the company holds more cash than debt and maintains strong liquidity, with current assets exceeding short-term obligations by 3.6x. According to InvestingPro’s Fair Value model, the stock appears undervalued at current levels.
In other recent news, HOOKIPA Pharma Inc. announced its decision to voluntarily delist from the Nasdaq Capital Market. This move comes in the wake of an asset purchase agreement with Gilead Sciences, Inc., signed on May 21. Under the agreement, Gilead will acquire HOOKIPA’s assets related to its HB-400 hepatitis B virus program and certain assets from its HB-500 HIV program. This development marks a significant strategic shift for HOOKIPA Pharma. The company also plans to deregister its common stock under the Securities Exchange Act of 1934. These recent developments highlight a major transition for HOOKIPA as it realigns its business focus.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.